FCAR

Summary

FCAR (Fc alpha receptor, HGNC:3608) is a protein-coding gene on chromosome 19q13.42, encoding Immunoglobulin alpha Fc receptor (P24071). Binds to the Fc region of immunoglobulins alpha.

This gene is a member of the immunoglobulin gene superfamily and encodes a receptor for the Fc region of IgA. The receptor is a transmembrane glycoprotein present on the surface of myeloid lineage cells such as neutrophils, monocytes, macrophages, and eosinophils, where it mediates immunologic responses to pathogens. It interacts with IgA-opsonized targets and triggers several immunologic defense processes, including phagocytosis, antibody-dependent cell-mediated cytotoxicity, and stimulation of the release of inflammatory mediators. Multiple alternatively spliced transcript variants encoding different isoforms have been described for this gene.

Source: NCBI Gene 2204 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 71 total
• MANE Select transcript: NM_002000

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3608
Approved symbol	FCAR
Name	Fc alpha receptor
Location	19q13.42
Locus type	gene with protein product
Status	Approved
Aliases	CD89, FcalphaRI, FcalphaR
Ensembl gene	ENSG00000186431
Ensembl biotype	protein_coding
OMIM	147045
Entrez	2204

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 9 protein_coding, 3 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000345937, ENST00000353758, ENST00000355524, ENST00000359272, ENST00000391723, ENST00000391724, ENST00000391725, ENST00000391726, ENST00000469767, ENST00000471750, ENST00000472634, ENST00000482092, ENST00000488066

RefSeq mRNA: 8 — MANE Select: NM_002000 NM_002000, NM_133269, NM_133271, NM_133272, NM_133273, NM_133274, NM_133277, NM_133278

CCDS: CCDS12907, CCDS12908, CCDS12909, CCDS12910, CCDS42622, CCDS42623, CCDS42624, CCDS42625

Canonical transcript exons

ENST00000355524 — 5 exons

Exon	Start	End
ENSE00001256400	54888007	54888294
ENSE00001938699	54889649	54891420
ENSE00003617918	54875330	54875365
ENSE00003626902	54885235	54885525
ENSE00003843913	54874235	54874323

Expression profiles

Bgee: expression breadth ubiquitous, 150 present calls, max score 93.17.

FANTOM5 (CAGE): breadth broad, TPM avg 22.0564 / max 2928.3610, expressed in 321 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
177557	19.2334	311
177558	2.3452	80
177556	0.4779	95

Top tissues by expression

290 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
monocyte	CL:0000576	93.17	gold quality
mononuclear cell	CL:0000842	92.78	gold quality
leukocyte	CL:0000738	92.18	gold quality
bone marrow	UBERON:0002371	91.40	gold quality
bone marrow cell	CL:0002092	89.67	gold quality
blood	UBERON:0000178	86.17	gold quality
right lung	UBERON:0002167	83.34	gold quality
granulocyte	CL:0000094	83.08	gold quality
spleen	UBERON:0002106	79.51	gold quality
vermiform appendix	UBERON:0001154	76.86	gold quality
upper lobe of left lung	UBERON:0008952	76.28	gold quality
upper lobe of lung	UBERON:0008948	73.61	gold quality
endometrium epithelium	UBERON:0004811	71.34	gold quality
caecum	UBERON:0001153	70.88	gold quality
buccal mucosa cell	CL:0002336	70.83	silver quality
left uterine tube	UBERON:0001303	68.64	gold quality
omental fat pad	UBERON:0010414	68.11	gold quality
peritoneum	UBERON:0002358	68.04	gold quality
gall bladder	UBERON:0002110	66.83	gold quality
adipose tissue of abdominal region	UBERON:0007808	66.65	gold quality
smooth muscle tissue	UBERON:0001135	63.61	gold quality
lung	UBERON:0002048	62.47	gold quality
descending thoracic aorta	UBERON:0002345	61.25	gold quality
trabecular bone tissue	UBERON:0002483	60.69	silver quality
right lobe of liver	UBERON:0001114	60.17	gold quality
mucosa of stomach	UBERON:0001199	59.60	gold quality
hindlimb stylopod muscle	UBERON:0004252	59.43	gold quality
lower esophagus mucosa	UBERON:0035834	59.21	gold quality
subcutaneous adipose tissue	UBERON:0002190	59.18	gold quality
right atrium auricular region	UBERON:0006631	58.99	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-MTAB-9801	yes	8.61
E-ANND-3	no	1.37

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CEBPA

miRNA regulators (miRDB)

112 targeting FCAR, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-LET-7F-5P	99.98	72.56	1784
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790
HSA-LET-7G-5P	99.98	72.37	1784
HSA-LET-7I-5P	99.98	72.37	1788
HSA-MIR-98-5P	99.98	72.33	1787
HSA-MIR-485-3P	99.98	70.68	1585
HSA-MIR-539-3P	99.98	70.74	1616
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562

Literature-anchored findings (GeneRIF, showing 36)

• CD89 circulates in a high molecular mass form in complex covalently linked to IgA and contributes to the formation of polymeric serum IgA. (PMID:11801662)
• study suggests that expression of the FcR splice isoform DeltaEC2 but not Delta66EC2 is differentially regulated in a cell type-specific manner and in response to inflammatory and/or infectious processes (PMID:12560105)
• The Fc alpha receptor 5’-flanking region from -102 to -64 relative to the ATG translation initiation codon is essential for promoter activity and contains two functional binding motifs for C/EBP and Ets family members at -74 and -92, respectively. (PMID:12594283)
• there is a bivalent, pH-dependent interaction between FcalphaRI and IgA with important implications for cytokine-dependent phagocytosis of IgA and the FcalphaRI-mediated degradation or recycling of IgA (PMID:12634059)
• crystal structures of human FcalphaRI alone and in a complex with the Fc region of IgA1 (Fcalpha) (PMID:12768205)
• Crystal structure of the ectodomain of human FcalphaRI (PMID:12783876)
• expression pattern of CD89 and its signalling subunit, the FcR gamma chain, on circulating myeloid cells and in various tissues (PMID:12791088)
• FcalphaRI expressed by interstitial-type dendritic cells could play a critical role to sample IgA-recognized antigens and also during dendritic cell activation. (PMID:15371488)
• Pathogenic group A and group B streptococci are well known to produce virulence factors that block the binding of IgA to the leukocyte IgA receptor, Fc alphaRI, thereby inhibiting IgA-mediated immunity. (PMID:16293625)
• Fc receptor gamma RI interacts with the unrelated immunoreceptors FcalphaRI and FcepsilonRI [FCalphaRI, also called CD89] (PMID:16627486)
• These results indicate that GPVI is unique amongst the receptors of its family as it uses different structural domains to interact with several agonists and provide evidence that different sites on GPVI constitute targets to develop antagonists of GPVI. (PMID:16876821)
• On monomeric targeting, FcalphaRI functions as an FcRgamma ITAM-dependent apoptotic module that may be fundamental for controlling inflammation and tumor growth. (PMID:16990604)
• Carriers of 92Asn polymorphism in the myeloid IgA Fc receptor had increased risk of myocardial infarction in CARE and increased odds of coronary heart disease in WOSCOPS study groups. (PMID:17008591)
• FCAR promoter SNPs may be related to chronic HCV infection and disease progression in Japanese chronic hepatitis C. (PMID:17033823)
• Fc alpha receptor type I activation mediates glomerulonephritis progression by initiating a cytokine/chemokine cascade that promotes leukocyte recruitment and kidney damage in transgenic mice. (PMID:17393381)
• Pathogen selection by bacterial decoy proteins drives FcalphaRI and IgA-Fc coevolution. (PMID:17548632)
• results suggest an endogenous mechanism by which FcalphaR functionality is down-regulated in an ‘allergic environment’ where FcepsilonRI is co-expressed and extensively cross-linked on FcalphaR-expressing effector cells (PMID:18700185)
• Immunoglobulin A: Fc(alpha)RI interactions induce neutrophil migration through release of leukotriene B4. (PMID:19555692)
• Endocytosis of FcalphaR is clathrin- and dynamin-dependent, but is not regulated by Rab5, and the endocytic motif is not located in the cytoplasmic domain of FcalphaR. (PMID:19859085)
• There is an association between the levels of sCD89-IgA complexes in serum and the severity of IgA nephropathy, and a possible genetic component in regulating the production or expression of sCD89. (PMID:20811333)
• Data show that the Fc(alpha)RI 844 A>G polymorphism is not associated with systemic sclerosis or rheumatoid arthritis sceptibility. (PMID:21159834)
• Genetic variation at the promoter region of IgA receptor is associated with IgA nephropathy. (PMID:21273231)
• FcalphaRI defines a function for pentraxins in inflammatory responses involving neutrophils and macrophages. It also highlights the innate aspect of otherwise humoral immunity-associated antibody receptors. (PMID:21383176)
• In this study, human mammary carcinoma cells are efficiently killed when incubated with human neutrophils and tumor-specific FcalphaRI bispecific or immunoglobulin A antibodies. (PMID:21653835)
• FCAR polymorphism is not associated with high susceptibility to IGA nephropathy in caucasians. (PMID:21750160)
• Glycosylation of the CH2/CH3 interface inhibits interaction with the pathogen IgA binding protein SSL7, while maintaining binding of pIgR, essential to the biosynthesis and transport of SIgA. (PMID:21784854)
• Abnormally glycosylated IgA1 and soluble CD89-IgA and IgA-IgG complexes, features of primary IgA nephropathy, are also present in alcoholic cirrhosis. (PMID:21866091)
• These results suggest a role of anti-FcaRI Fab as a negative regulator in controlling the magnitude of the innate immune response (PMID:21985370)
• this study examined the expression of IL-4 mRNA, IFN-c mRNA and FcaRI mRNA in tonsillar mononuclear cells of IgA nephropathy9(IgAN) patients and non-IgAN patients. (PMID:24732061)
• induces different forms of neutrophil death, depending on the inflammatory microenvironment (PMID:25339672)
• Findings suggest a basis for the use of Fc receptor I for IgA (FcalphaRI) as a molecular target for the treatment of lupus. (PMID:25907714)
• In transgenic mice, IgAN pathogenesis involves impaired clearance of abnormal IgA via CD89, primarily by the Kupffer cells. Conditional IgAN progression in CD89 transgenic mice thus reveals important aspects of IgAN pathogenesis. (PMID:27437939)
• a novel Fcar splice variant termed variant APD isolated from a healthy volunteer that lacks only the IgA-binding EC1 domain, is reported. (PMID:28103138)
• FcalphaRI-induced cytokine production is orchestrated via upregulation of cytokine translation and caspase-1 activation, which is dependent on glycolytic reprogramming. (PMID:29491406)
• Serum Soluble CD89-IgA Complexes Are Elevated in IgA Nephropathy without Immunosuppressant History. (PMID:32076466)
• SIgA structures bound to Streptococcus pyogenes M4 and human CD89 provide insights into host-pathogen interactions. (PMID:37872175)

Cross-species orthologs

0 orthologs

Paralogs (25): GP6 (ENSG00000088053), LILRB1 (ENSG00000104972), LILRA1 (ENSG00000104974), LILRB5 (ENSG00000105609), A1BG (ENSG00000121410), KIR2DL1 (ENSG00000125498), LILRB2 (ENSG00000131042), IGSF1 (ENSG00000147255), LAIR2 (ENSG00000167618), KIR3DL1 (ENSG00000167633), OSCAR (ENSG00000170909), LILRB4 (ENSG00000186818), LILRA5 (ENSG00000187116), KIR2DL4 (ENSG00000189013), VSTM1 (ENSG00000189068), NCR1 (ENSG00000189430), LILRB3 (ENSG00000204577), KIR2DS4 (ENSG00000221957), LILRA4 (ENSG00000239961), LILRA2 (ENSG00000239998), KIR3DL2 (ENSG00000240403), KIR3DL3 (ENSG00000242019), KIR2DL3 (ENSG00000243772), LILRA6 (ENSG00000244482), TARM1 (ENSG00000248385)

Protein

Protein identifiers

Immunoglobulin alpha Fc receptor — P24071 (reviewed: P24071)

All UniProt accessions (1): P24071

UniProt curated annotations — full annotation on UniProt →

Function. Binds to the Fc region of immunoglobulins alpha. Mediates several functions including cytokine production.

Subunit / interactions. Associates with the Fc epsilon RI gamma 2 receptor inducing tyrosine phosphorylation of gamma 2. (Microbial infection) Interacts with Staphylococcus aureus protein SSL11.

Subcellular location. Cell membrane Cell membrane Cell membrane Secreted Secreted.

Tissue specificity. Isoform A.1, isoform A.2 and isoform A.3 are differentially expressed between blood and mucosal myeloid cells. Isoform A.1, isoform A.2 and isoform A.3 are expressed in monocytes. Isoform A.1 and isoform A.2 are expressed in alveolar macrophages; however only one isoform is expressed at alveolar macrophages surfaces.

Miscellaneous. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay.

Isoforms (11)

UniProt ID	Names	Canonical?
P24071-1	A.1	yes
P24071-2	A.2
P24071-3	A.3, RLA2
P24071-4	B
P24071-5	B-delta-S2
P24071-6	U02
P24071-7	L10
P24071-8	U09
P24071-9	U10
P24071-10	U11
P24071-11	U13

RefSeq proteins (8): NP_001991, NP_579803, NP_579805, NP_579806, NP_579807, NP_579808, NP_579811, NP_579812 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003599	Ig_sub	Domain
IPR013151	Immunoglobulin_dom	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR050412	Ig-like_Receptors_ImmuneReg	Family

Pfam: PF00047

UniProt features (49 total): strand 21, splice variant 8, glycosylation site 5, helix 3, disulfide bond 2, topological domain 2, sequence variant 2, domain 2, signal peptide 1, chain 1, transmembrane region 1, turn 1

Structure

Experimental structures (PDB)

6 structures.

PDB	Method	Resolution (Å)
9OFS	X-RAY DIFFRACTION	1.95
1UCT	X-RAY DIFFRACTION	2.1
9OFR	X-RAY DIFFRACTION	2.65
1OVZ	X-RAY DIFFRACTION	3
1OW0	X-RAY DIFFRACTION	3.1
8SKU	ELECTRON MICROSCOPY	3.2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P24071-F1	83.61	0.60

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (2): 49–100, 146–193

Glycosylation sites (5): 177, 186, 65, 79, 141

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-6798695	Neutrophil degranulation

MSigDB gene sets: 161 (showing top): REACTOME_INNATE_IMMUNE_SYSTEM, GOBP_MYELOID_CELL_HOMEOSTASIS, GOBP_POSITIVE_REGULATION_OF_LEUKOCYTE_APOPTOTIC_PROCESS, GOBP_RESPONSE_TO_PEPTIDE, GOBP_REGULATION_OF_LEUKOCYTE_APOPTOTIC_PROCESS, GOBP_CELLULAR_RESPONSE_TO_LIPID, GOCC_SECRETORY_GRANULE, GOBP_CELLULAR_RESPONSE_TO_BIOTIC_STIMULUS, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GOBP_LEUKOCYTE_MEDIATED_IMMUNITY, GOBP_RESPONSE_TO_INTERFERON_ALPHA, TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_ERYTHROCYTE_UP, GOBP_REGULATION_OF_IMMUNE_RESPONSE, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, GOBP_MYELOID_LEUKOCYTE_ACTIVATION

GO Biological Process (12): neutrophil mediated immunity (GO:0002446), immune response-regulating signaling pathway (GO:0002764), immune response (GO:0006955), positive regulation of neutrophil apoptotic process (GO:0033031), cellular response to interferon-alpha (GO:0035457), Fc receptor signaling pathway (GO:0038093), neutrophil activation (GO:0042119), cellular response to lipopolysaccharide (GO:0071222), cellular response to type II interferon (GO:0071346), cellular response to interleukin-6 (GO:0071354), cellular response to tumor necrosis factor (GO:0071356), cellular response to granulocyte macrophage colony-stimulating factor stimulus (GO:0097011)

GO Molecular Function (2): IgA receptor activity (GO:0019766), IgA binding (GO:0019862)

GO Cellular Component (6): extracellular region (GO:0005576), plasma membrane (GO:0005886), specific granule membrane (GO:0035579), tertiary granule membrane (GO:0070821), ficolin-1-rich granule membrane (GO:0101003), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Innate Immune System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular response to cytokine stimulus	5
secretory granule membrane	3
cellular anatomical structure	2
tertiary granule	2
myeloid leukocyte mediated immunity	1
signal transduction	1
regulation of immune response	1
immune system process	1
response to stimulus	1
neutrophil apoptotic process	1
positive regulation of immune system process	1
regulation of neutrophil apoptotic process	1
positive regulation of myeloid cell apoptotic process	1
positive regulation of leukocyte apoptotic process	1
response to interferon-alpha	1
immune response-regulating cell surface receptor signaling pathway	1
granulocyte activation	1
response to lipopolysaccharide	1
cellular response to molecule of bacterial origin	1
cellular response to lipid	1
cellular response to oxygen-containing compound	1
response to type II interferon	1
response to interleukin-6	1
response to tumor necrosis factor	1
response to granulocyte macrophage colony-stimulating factor	1
immunoglobulin receptor activity	1
IgA binding	1
immunoglobulin binding	1
membrane	1
cell periphery	1
specific granule	1
ficolin-1-rich granule	1

Protein interactions and networks

STRING

1084 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FCAR	FCER1G	P30273	977
FCAR	PIGR	P01833	905
FCAR	FCAMR	Q8WWV6	844
FCAR	FCGR1A	P12314	841
FCAR	FCGR2A	P12318	833
FCAR	TYROBP	O43914	819
FCAR	FCGR3B	O75015	785
FCAR	FCGR3A	P08637	783
FCAR	TFRC	P02786	760
FCAR	CRP	P02741	759
FCAR	FCER1A	P12319	739
FCAR	FCGRT	P55899	733
FCAR	CD300C	Q08708	728
FCAR	JCHAIN	P01591	715
FCAR	ASGR1	P07306	641

IntAct

18 interactions, top by confidence:

A	B	Type	Score
FCAR	IGHA1	psi-mi:“MI:0407”(direct interaction)	0.440
FCAR	EFR3B	psi-mi:“MI:0915”(physical association)	0.400
FCAR	PBLD	psi-mi:“MI:0915”(physical association)	0.400
FCAR	sl11	psi-mi:“MI:0915”(physical association)	0.400
FCAR	LILRB2	psi-mi:“MI:0915”(physical association)	0.400
FCAR	CD33	psi-mi:“MI:0915”(physical association)	0.400
FCAR	IFNGR1	psi-mi:“MI:0915”(physical association)	0.400
FCAR	PDCD1LG2	psi-mi:“MI:0915”(physical association)	0.400
FCAR	SIGLEC10	psi-mi:“MI:0915”(physical association)	0.400
FCAR	SIGLEC14	psi-mi:“MI:0915”(physical association)	0.400
FCAR	SIGLEC6	psi-mi:“MI:0915”(physical association)	0.400
IFNGR1	FCAR	psi-mi:“MI:0915”(physical association)	0.400
LILRB2	FCAR	psi-mi:“MI:0915”(physical association)	0.400
FCAR	PIGR	psi-mi:“MI:0915”(physical association)	0.400
ECE1	FCAR	psi-mi:“MI:0915”(physical association)	0.370
M		psi-mi:“MI:0914”(association)	0.350

BioGRID (11): HAL (Affinity Capture-MS), EFR3B (Affinity Capture-MS), FCAR (Affinity Capture-Western), FCER1G (Affinity Capture-Western), EFR3B (Affinity Capture-MS), FCAR (Affinity Capture-Western), FCGR1A (Affinity Capture-Western), EFR3B (Affinity Capture-MS), LYN (Affinity Capture-Western), PBLD (Affinity Capture-MS), FCGR1A (Affinity Capture-Western)

ESM2 similar proteins: A0A0E4BZH1, A4QPC6, A5D7V5, A7TZE6, A7TZF0, A7TZF3, A7XUX6, A7XV04, A7XV07, A8K4G0, A8MVZ5, O70355, P08508, P18892, P24071, P31994, P55803, P78410, P79391, Q13410, Q16653, Q29ZQ1, Q3KPI0, Q58DF9, Q5R7W8, Q5R960, Q5R996, Q61885, Q62556, Q63345, Q6Q8B3, Q6UXZ3, Q6XJV4, Q6XJV6, Q7KYR7, Q7TST0, Q7YR73, Q8BTP3, Q8K249, Q8TD46

Diamond homologs: A0A0G2KBC9, A6NI73, C0HJX2, C0HJX3, D3ZQX2, O75019, O75022, O75023, O76036, P0C191, P24071, P43626, P43629, P43630, P59901, P83556, P97484, Q14943, Q14954, Q61450, Q64281, Q6GTX8, Q6ISS4, Q6PI73, Q7TQA1, Q863H2, Q8C567, Q8IYS5, Q8MJZ2, Q8MJZ7, Q8N109, Q8N149, Q8N423, Q8N6C8, Q8N743, Q8NHJ6, Q8NHK3, Q8NHL6, Q95JB9, Q9HCN6

SIGNOR signaling

7 interactions.

A	Effect	B	Mechanism
FCAR	up-regulates	Cytokine_production
FCAR	up-regulates	Phagocytosis
FCAR	up-regulates	Immune_response
GSK3A	“down-regulates activity”	FCAR	phosphorylation
GSK3B	“down-regulates activity”	FCAR	phosphorylation
PPP2CA	“up-regulates activity”	FCAR	dephosphorylation
“Immune complexes”	“up-regulates activity”	FCAR	relocalization

Disease & clinical

Clinical variants and AI predictions

ClinVar

71 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	58
Likely benign	8
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

941 predictions. Top by Δscore:

Variant	Effect	Δscore
19:54875328:A:AG	acceptor_gain	1.0000
19:54875329:G:GG	acceptor_gain	1.0000
19:54889646:CAG:C	acceptor_loss	1.0000
19:54889647:A:AG	acceptor_gain	1.0000
19:54889647:A:AT	acceptor_loss	1.0000
19:54889648:G:GA	acceptor_gain	1.0000
19:54889648:GA:G	acceptor_gain	1.0000
19:54889648:GACT:G	acceptor_gain	1.0000
19:54889648:GACTC:G	acceptor_gain	1.0000
19:54874322:TGG:T	donor_loss	0.9900
19:54874324:GT:G	donor_loss	0.9900
19:54875329:GT:G	acceptor_gain	0.9900
19:54875367:T:A	donor_loss	0.9900
19:54885448:C:T	donor_gain	0.9900
19:54885523:CAGGT:C	donor_loss	0.9900
19:54885524:AGGTA:A	donor_loss	0.9900
19:54885526:G:C	donor_loss	0.9900
19:54885527:T:A	donor_loss	0.9900
19:54888006:GGCTT:G	acceptor_gain	0.9900
19:54889640:T:TA	acceptor_gain	0.9900
19:54889646:CAGA:C	acceptor_gain	0.9900
19:54889648:GAC:G	acceptor_gain	0.9900
19:54874324:G:GG	donor_gain	0.9800
19:54874326:GAG:G	donor_loss	0.9800
19:54885233:A:AG	acceptor_gain	0.9800
19:54885233:AG:A	acceptor_gain	0.9800
19:54885233:AGG:A	acceptor_gain	0.9800
19:54885233:AGGG:A	acceptor_gain	0.9800
19:54885234:G:GG	acceptor_gain	0.9800
19:54885234:GG:G	acceptor_gain	0.9800

AlphaMissense

1881 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:54888222:T:A	C193S	0.987
19:54888223:G:C	C193S	0.987
19:54888111:T:C	F156L	0.985
19:54888113:T:A	F156L	0.985
19:54888113:T:G	F156L	0.985
19:54888267:A:C	S208R	0.984
19:54888269:T:A	S208R	0.984
19:54888269:T:G	S208R	0.984
19:54885309:T:A	C49S	0.983
19:54885310:G:C	C49S	0.983
19:54885456:T:G	Y98D	0.983
19:54888081:T:A	C146S	0.982
19:54888082:G:C	C146S	0.982
19:54885462:T:A	C100S	0.981
19:54885463:G:C	C100S	0.981
19:54888222:T:C	C193R	0.980
19:54888083:C:G	C146W	0.979
19:54888224:C:G	C193W	0.979
19:54888177:T:C	F178L	0.975
19:54888179:C:A	F178L	0.975
19:54888179:C:G	F178L	0.975
19:54888216:T:G	Y191D	0.973
19:54888268:G:T	S208I	0.973
19:54888081:T:C	C146R	0.971
19:54888223:G:A	C193Y	0.971
19:54888082:G:A	C146Y	0.970
19:54885417:T:C	F85L	0.969
19:54885419:C:A	F85L	0.969
19:54885419:C:G	F85L	0.969
19:54888102:T:C	F153L	0.968

dbSNP variants (sampled 300 via entrez): RS1000259878 (19:54885844 G>A,C,T), RS1000280412 (19:54881770 G>A), RS1000294146 (19:54876464 T>C), RS1000319943 (19:54876344 G>A), RS1000364978 (19:54881369 C>A,G), RS1000573830 (19:54886108 C>A,G,T), RS1000653620 (19:54880650 T>C), RS1000966533 (19:54889337 A>C,T), RS1001035036 (19:54879379 T>C,G), RS1001066979 (19:54890512 C>G), RS1001473446 (19:54873297 G>A), RS1001499563 (19:54882132 G>T), RS1001738478 (19:54891285 G>A,C), RS1001829974 (19:54880900 A>G), RS1001903518 (19:54880739 G>A)

Disease associations

OMIM: gene MIM:147045 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST004133_69	Ulcerative colitis	1.000000e-07

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs11666735	FCAR		0.00	0

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: other protein — CD molecules

Most potent curated ligand interactions (1 total), top 1:

Ligand	Action	Affinity	Parameter
BsAb (CD89-CD20)	Binding	8.49	pKd

CTD chemical–gene interactions

25 total (human), top 25 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases reaction, increases expression, affects methylation, decreases methylation	3
triphenyl phosphate	affects expression	1
sulforaphane	increases expression	1
3,4,5,3’,4’-pentachlorobiphenyl	increases expression	1
di-n-butylphosphoric acid	affects expression	1
fipronil	decreases expression	1
CGP 52608	affects binding, increases reaction	1
erucylphospho-N,N,N-trimethylpropylammonium	increases expression	1
abrine	increases expression	1
bisphenol S	decreases methylation	1
gardiquimod	decreases expression, decreases reaction	1
Cadmium	decreases expression, increases abundance	1
Cisplatin	increases expression	1
Dactinomycin	increases expression, decreases reaction	1
Dust	increases expression	1
Folic Acid	increases expression	1
Gasoline	increases abundance, increases expression, affects cotreatment	1
Methylcholanthrene	increases expression	1
Phthalic Acids	increases methylation	1
Polycyclic Aromatic Hydrocarbons	increases expression, affects cotreatment, increases abundance	1
Tretinoin	increases expression	1
Antirheumatic Agents	decreases expression	1
Cadmium Chloride	decreases expression, increases abundance	1
Protein Kinase Inhibitors	decreases expression, decreases reaction	1
Particulate Matter	increases abundance, increases expression, affects cotreatment	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_1F83	TZM-bl/FcalphaR	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.